EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab

Georgios Axiaris, Alexandros Ioannou iD, Marina Papoutsaki, Leonidas Marinos, Michael Liontos, Spyridon Michopoulos, Evanthia Zampeli

F1000Research · 2023

DOI: 10.12688/f1000research.110356.2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift F1000Research, 2023. Verfasst von Georgios Axiaris und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Alexandra General Hospital, Athens, Greece, 11528, Greece. Hauptthemen laut MEDLINE: Crohn Disease, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cornerstone of inflammatory bowel disease (IBD) treatment is immunomodulators. IBD patients are at increased risk of intestinal and extraintestinal malignancy. Ustekinumab is a fully humanized monoclonal anti-IL12/23 antibody with a good safety profile. Malignancies of breast, colon, head and neck, kidney, prostate, thyroid, and non-melanoma skin cancer have been reported among patients who received ustekinumab. We report the case of a 42-year-old Crohn’s patient on long-term treatment with ustekinumab, who developed achromatic malignant melanoma. Crohn’s was diagnosed at the age of 15, with upper and lower gastrointestinal involvement and was initially treated with azathioprine (2mg/kg for 4 years) and infliximab (5mg/kg for 6 weeks). Due to ileal obstruction, the patient underwent stricturoplasty and received adalimumab (40mg every other week) for two years. He then discontinued therapy and a year later underwent right hemicolectomy. Adalimumab was reinstituted (40mg every other week) and the patient remained in clinical remission for two years. His overall exposure to adalimumab was four years. Ustekinumab was initiated due to a relapse and after 3 years, an incident of scalp itching led to the diagnosis metastatic achromatic malignant melanoma bearing BRAF V600E mutation. He received targeted therapy with an initial good response. We aim to point out the risk of dermatologic malignancy in IBD patients on long-term immunosuppression and the lifelong and meticulous evaluation that is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseMelanomaSkin NeoplasmsMaleHumansChild, PreschoolAdultUstekinumabAdalimumabAntibodies, Monoclonal, HumanizedCutaneous Malignant Melanoma

Stichwörter der Autor:innen

Crohn’s diseaseIBDMelanomaUstekinumab

Substanzen

UstekinumabAdalimumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Gastroenterology Department, Alexandra General Hospital, Athens, Greece, 11528, Greece.
  • Dermatology Department, Syggros Hospital, Athens, Greece, 11528, Greece.
  • Pathology Department, Evangelismos Hospital, Atherns, Greece, 11528, Greece.
  • Oncology Department, Alexandra General Hospital, Athens, Greece, 11528, Greece.

ORCID-Profile: Alexandros Ioannou

Zitieren

APA

Axiaris, G., Ioannou, A., Papoutsaki, M., Marinos, L., Liontos, M., Michopoulos, S., & Zampeli, E. (2023). Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab. F1000Research. https://doi.org/10.12688/f1000research.110356.2

Vancouver

Axiaris G, Ioannou A, Papoutsaki M, Marinos L, Liontos M, Michopoulos S, et al. Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab. F1000Research. 2023. doi:10.12688/f1000research.110356.2

BibTeX
@article{Axiaris2023,
  author = {Axiaris, Georgios and Ioannou, Alexandros and Papoutsaki, Marina and Marinos, Leonidas and Liontos, Michael and Michopoulos, Spyridon and Zampeli, Evanthia},
  title = {Case Report: Malignant melanoma in a patient with Crohn’s disease treated with ustekinumab},
  journal = {F1000Research},
  year = {2023},
  doi = {10.12688/f1000research.110356.2}
}
Kostenlos starten →